Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,472.00
Bid: 12,492.00
Ask: 12,496.00
Change: 74.00 (0.60%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,526.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Sterling steadies vs dollar, euro after profit-taking knock

Thu, 08th Apr 2021 12:38

* Pound edges up vs dollar, flat vs sterling

* Graphic: World FX rates in 2021 http://tmsnrt.rs/2egbfVh

* Graphic: Trade-weighted sterling since Brexit vote http://tmsnrt.rs/2hwV9Hv
(Updates prices)

By Tom Wilson

LONDON, April 8 (Reuters) - Sterling steadied against the
dollar and euro on Thursday, recovering after a bruising bout of
profit-taking earlier in the week.

The pound fell 1.2% against the dollar and 1.7% against the
euro between Tuesday and Wednesday as investors took cash off
the table after a strong first quarter for the British currency.

But by 1500 GMT on Thursday, sterling was up 0.15% against
the dollar at $1.3760, after touching its lowest this
month earlier in the day as the dollar traded near its lowest in
two weeks versus major peers.

Against the euro, the pound fell 0.1% to 86.49 pence per
euro, following two days of losses against the
single currency since September - a fall traders said was
amplified by a squeeze of euro-pound short positions.

Traders were largely optimistic over the pound's near-term
prospects after a strong start to the year. But some urged
caution as markets have already priced in positive news for
sterling.

Sterling's pullback was "exaggerated," ING analysts wrote,
adding that they were "constructive" on the pound, citing
Britain's relatively fast COVID-19 vaccine programme.

Expectations of an economic rebound in Britain, spurred by
rapid vaccinations, helped sterling to record its best quarter
since 2015 versus the euro. Falling expectations of negative
interest rates also helped.

Britain has surged ahead of the rest of Europe in the race
to inoculate its population, with almost half of its citizens
receiving a first dose. But supply issues from its main
Oxford-AstraZeneca vaccine have slowed progress in
recent days.

Some market players said the pound may struggle to maintain
its strong start to the year.

"We are starting what's likely to be much more challenging
quarter for sterling," said Adam Cole, chief currency strategist
at RBC Capital Markets, with positive news on vaccines and the
lower risk of negative rates already priced in.

Others said Britain's economic performance in the next
quarter would be a key factor. With infection numbers falling, a
planned partial re-opening of the economy is due next week.

"For there to be follow through, we actually need to see the
data outperform even expectations," said Stephen Gallo, European
head of FX strategy at BMO Capital Markets.
(Reporting by Tom Wilson;
editing by Mark Heinrich, Chizu Nomiyama, Larry King)

More News
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more
25 Apr 2024 07:43

LONDON BRIEFING: Miner Anglo American eyes rival BHP takeover

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 06:30

Sanofi Q1 profit slips on generic competition, forex effects

April 25 (Reuters) - Sanofi's said on Thursday first-quarter operating income declined 14.7% as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.